Pelthos Therapeutics Maps Public-Market Path, ZELSUVMI Surge, Adds Xepi and Xeglyze in Roth Interview [Yahoo! Finance]
Pelthos Therapeutics Inc. (PTHS)
Company Research
Source: Yahoo! Finance
commercial traction for its lead product ZELSUVMI, and plans to add two additional pediatric-focused dermatology products during an investor interview hosted by Roth Capital Partners senior biotechnology analyst Jonathan Aschoff. How Pelthos became public and current capitalization Chief Executive Officer Scott Plesha said Pelthos and its topical product ZELSUVMI were previously housed within Ligand as a subsidiary for roughly 18 to 24 months. On July 1, 2025, the business merged into Channel Therapeutics and the combined company was renamed Pelthos, which Plesha said was driven in part by “brand equity” that had developed with potential ZELSUVMI prescribers. ? Quiet BNY and Northern Trust Reward Patient Investors The company also raised a $50 million PIPE at the time of the merger and began trading on the New York Stock Exchange under ticker PTHS, according to management. Chief Financial Officer Frank Knuettel II said Channel had gone public on NYSE American in February 202
Show less
Read more
Impact Snapshot
Event Time:
PTHS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PTHS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PTHS alerts
High impacting Pelthos Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
PTHS
News
- Pelthos Therapeutics to Participate in Piper Sandler Spring Biopharma SymposiumGlobeNewswire
- Pelthos Therapeutics Announces CFO TransitionGlobeNewswire
- Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye PainGlobeNewswire
- Pelthos Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Pelthos Therapeutics Inc (PTHS) Q4 2025 Earnings Call Highlights: Prescription Surge and ... [Yahoo! Finance]Yahoo! Finance
PTHS
Earnings
- 3/19/26 - Miss
PTHS
Sec Filings
- 4/14/26 - Form 8-K
- 4/10/26 - Form 8-K
- 4/6/26 - Form 4
- PTHS's page on the SEC website